Related Experiment Video
Updated: Jun 15, 2025
A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy
Published on: November 7, 2017
Association of hyperuricemia with coronary heart disease: Protocol for an updated systematic review and dose-response
Jinling Chen1, Yi Pan2, Qun Gao2
1Department of Cardiology, Beijing Pinggu Hospital, Beijing, China.
Insights
This systematic review and meta-analysis will investigate the link between high uric acid levels (hyperuricemia) and coronary heart disease (CHD). Findings will clarify hyperuricemia as a potential cardiovascular risk factor.
Area of Science:
- Cardiovascular Research
- Epidemiology
- Metabolic Syndrome
Background:
- Hyperuricemia, defined by elevated serum uric acid, is increasingly studied for its role in cardiovascular disease.
- Conflicting evidence exists regarding hyperuricemia as an independent risk factor for coronary heart disease (CHD).
- A comprehensive synthesis of existing data is needed to clarify this association.
Purpose of the Study:
- To systematically review and quantitatively analyze the association between hyperuricemia and CHD risk.
- To conduct a dose-response meta-analysis to explore the relationship between serum uric acid levels and CHD.
- To provide robust evidence for clinical practice and future research in cardiovascular disease management.
Main Methods:
- A systematic search of major databases (Medline, EMBase, Cochrane Central, ICTRP, ClinicalTrials.gov) will be performed.
- Prospective and retrospective cohort and case-control studies will be included, with data extraction and risk of bias assessment by two independent reviewers.
- Random-effect models, dose-response meta-analysis, subgroup, sensitivity, and publication bias analyses will be employed, with GRADE assessing evidence quality.
Main Results:
- This systematic review and dose-response meta-analysis is expected to yield reliable conclusions on the association between hyperuricemia and CHD.
- The findings will offer data support for understanding hyperuricemia as a potentially modifiable risk factor for CHD.
- Transparent and replicable methodologies ensure the robustness of the expected results.
Conclusions:
- This protocol outlines a rigorous plan for a systematic review and meta-analysis on hyperuricemia and CHD risk.
- The study aims to clarify the quantitative association, aiding clinical practice and scientific inquiry.
- The findings will contribute to evidence-based strategies for cardiovascular disease prevention and management.
Introduction:
Hyperuricemia, characterized by elevated serum uric acid levels, has garnered significant attention in cardiovascular research due to its potential association with coronary heart disease (CHD). While some studies suggest hyperuricemia as a risk factor of CHD, others present conflicting findings. A systematic review and dose-response meta-analysis is warranted to comprehensively summarize the previous studies and determine the association between hyperuricemia and CHD, thereby supporting clinical practice and future studies in this field.
Methods:
In this study, we will comprehensively search Medline, EMBase, Cochrane Central, ICTRP, and ClinicalTrials.gov, from inception to December 31, 2024. Prospective or retrospective cohort studies and case-control studies investigating the association between hyperuricemia and CHD will be included. Two independent reviewers will conduct study selection, data extraction, and risk of bias assessment. The primary outcome will be the pooled relative risk of CHD associated with hyperuricemia by using random-effect model. Dose-response meta-analysis will be performed with linear and non-linear model to explore the the magnitude and direction of the association between serum uric acid levels and CHD risk. Subgroup analyses will be conducted based on uric acid test approaches and corresponding cut-off values and human races. Sensitivity analyses will assess the robustness of the results with leave-one-out method, while publication bias will be evaluated using funnel plots, Egger's test, and Begg's test. We will further use GRADE to evaluate the quality of the evidences provided by our systematic review.
Expected Results:
From this systematic review and dose-response meta-analysis, we hope out findings will provide reliable conclusion and data support on the association between hyperuricemia and CHD. The transparent and replicable methodologies outlined in this protocol contribute to advancing understanding of hyperuricemia as a potentially modifiable risk factor for CHD, thus supporting evidence-based strategies for cardiovascular disease management.
Conclusions:
This protocol describes a rigorous plan to systematically review and analyze the quantitative association between hyperuricemia and CHD risk. In a word, we will help further clinical practice and scientific studies in this field.
Trial Registration:
This protocol was registered in PROSPERO CRD42024538553.
More Related Videos
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:17Ischemic Heart Disease: Overview
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
01:20Exercise and Cardiovascular Response
Light to moderate physical activity initiates a series of interconnected responses in the body. The heart rate modestly increases in anticipation of the workout, followed by widespread vasodilation as oxygen consumption by skeletal muscles increases. This results in decreased peripheral resistance, increased capillary blood flow, and accelerated...
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
01:17Increased pulse rate
Many factors can elevate the risk of developing tachycardia. These include advanced age, a family history of arrhythmias, and an...
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...